Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics

Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics

Background: Mepolizumab treatment improves symptom control and quality of life and reduces exacerbations in patients with severe eosinophilic asthma. However, biomarkers that predict therapeutic effectiveness must be determined for use in precision medicine. Herein, we elucidated the dynamics of var...

Full description

Bibliographic Details
Main Authors: Hitoshi Sasano, Norihiro Harada, Sonoko Harada, Tomohito Takeshige, Yuuki Sandhu, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Tetsutaro Nagaoka, Jun Ito, Asako Chiba, Hisaya Akiba, Ryo Atsuta, Kenji Izuhara, Sachiko Miyake, Kazuhisa Takahashi
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Allergology International
Subjects:
Asthma
Mepolizumab
Mucosal-associated invariant T cells
Periostin
Type 2 airway inflammation
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893023000503

Internet

http://www.sciencedirect.com/science/article/pii/S1323893023000503

Similar Items